Cancer News

Cabometyx® Approved for Kidney Cancer

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy.

Each year in the United States, more than 61,000 people are diagnosed with kidney cancer. The most common type of kidney cancer is renal cell carcinoma (RCC), which starts in the lining of very small tubes (tubules) in the kidney. For people with advanced or metastatic RCC (cancer that has spread to other parts of the body), targeted therapies can play an important role in treatment. Approximately 20-30% of patients with RCC will have metastases at diagnosis and as many as 40% will demonstrate metastasis after treatment for earlier stage RCC. With a 5-year survival rate ranging from 5-10% for patients with advanced RCC, the overall prognosis for these patients is poor.

Cabozantinib is a kinase inhibitor that stops or decreases the action of many different cellular processes involved in cancer growth or spread. Cabozantinib is thought to inhibit the action of the receptor tyrosine kinases including MET, VEGFR-1, -2, and -3, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2.

The recent approval of cabozantinib was based on a trial including approximately 660 patients with advanced RCC who had received prior therapy with an anti-angiogenic agent. Patients in the trial were treated with either cabozantinib or the standard treatment agent, Afinitor® (everolimus).

  • Anti-cancer responses were achieved in 17% of patients treated with cabozantinib, compared with only 3% of patients treated with everolimus.
  • Median survival time without progression of cancer was 7.4 months for patients treated with cabozantinib, compared with 3.8 months for those treated with everolimus.
  • Median overall survival time was 21.4 months for patients treated with cabozantinib, compared with 16.5 months for patients treated with everolimus.

The most common serious side effects associated with cabozantinib were abdominal pain, excess fluid buildup around the lungs (pleural effusion), diarrhea, and nausea.

The approval of cabozantinib provides an additional treatment option for patients with advanced RCC, demonstrating improved outcomes compared to the historical standard therapy.

Reference: United States Food and Drug Administration (FDA). Cabozantinib (CABOMETYX). Available at: Accessed April 27, 2016.

Copyright © 2020 CancerConnect. All Rights Reserved.